An Open-Label Clinical Trial Evaluating Safety and Pharmacokinetics of Two Dosing Schedules of Panitumumab in Patients with Solid Tumors

Joe Stephenson(Neurology Centers of the Carolinas), Charles Gregory(Neurology Centers of the Carolinas), Howard A. Burris(Tennessee Oncology), Tim Larson, Udit Verma(Southwestern Medical Center), Allen Lee Cohn(Rocky Mountain Cancer Centers), Jeffrey Crawford(Duke Medical Center), Roger B. Cohen(Fox Chase Cancer Center), Julie Martin(Neurology Centers of the Carolinas), Peggy Lum(Amgen (United States)), Xinqun Yang(Amgen (United States)), Rafael G. Amado(Amgen (United States))

Clinical Colorectal Cancer

January 1, 2009

10.3816/ccc.2009.n.005

Cited by 42

Abstract

Related Papers

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al.|JNCI Journal of the National Cancer Institute|2000|15.7k

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Eric Van Cutsem, Marc Peeters, Salvatore Siena et al.|Journal of Clinical Oncology|2007|2k

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

Xiaodong Yang|Critical Reviews in Oncology/Hematology|2001|459

Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers

William J. Gullick|British Medical Bulletin|1991|449

High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History

Bert H. O’Neil, Robert M. Allen, David R. Spigel et al.|Journal of Clinical Oncology|2007|349